• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » European commission gives Thermo Fisher’s $3.5 billion Phadia buyout the green light | MassDevice.com On Call

European commission gives Thermo Fisher’s $3.5 billion Phadia buyout the green light | MassDevice.com On Call

August 26, 2011 By MassDevice staff

MassDevice On Call

MASSDEVICE ON CALL — The European Commission in Brussels cleared Thermo Fisher Scientific Inc.’s (NYSE:TMO) $3.5 billion cash buyout of Swedish blood test maker Phadia, finding that "the transaction would not raise competition concerns."

"After investigating the proposed transaction, the Commission determined that the parties are not close competitors and are currently primarily constrained by other competitors, which would continue to constrain the merged entity," according to a press release.

The acquisition, which was first announced in May, gives Thermo Fisher expanded reach in specialty diagnostics. Phadia supplies more than 70 percent of the world’s allergy laboratory tests and 40 percent of autoimmunity tests, according to a prepared release.

Phadia’s 1,500 global employees and approximately $525 million in revenue will be folded into Thermo Fisher’s specialty diagnostics unit.

In its quarterly earnings report, Thermo Fisher increased prior estimates for Phadia’s contribution to its bottom line, predicting a 7 cent bump for fiscal year 2011’s adjusted earnings per share from the merger. The Waltham, Mass.-based company also upped its full year adjusted EPS guidance to a new range of $4.15 to $4.25, which amounts to between 20 percent and 23 percent EPS growth compared to FY 2010.

Read MassDevice’s interview with Thermo Fisher CEO Marc Casper.

States plus D.C. defend individual insurance mandate

The individual insurance mandate in President Barack Obama’s health care reform bill, which has bounced back and forth between wins and losses in court, got a boost from 10 states and the District of Colombia, who filed briefs in support of the law, Law360.com reported (paid).

Imaging industry supports government efforts at preventing radiation exposure

The Medical Imaging & Technology Alliance gave efforts by the U.S. Joint Commission and others to protect patients from unnecessary medical radiation a thumbs up, according to a press release.

Vaccines mostly side-effect free

Immunizations don’t pose many side effects according to a meta-analysis of more than 1,000 studies conducted by the Institute of Medicine.

Is Google getting back into health records?

Just two months after shutting down Google Health, Google could be approaching online personal medical records from another angle with Google+, Xconomy reported.

Filed Under: Healthcare Reform, Legal News, Mergers & Acquisitions, News Well Tagged With: Alphabet (Google), Insurance, Phadia, Thermo Fisher Scientific

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy